# Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer

> **NCT05356585** · — · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Colorectal Cancer
- Rectal Cancer

## Interventions

- **GENETIC:** SignateraTM assay

## Key facts

- **NCT ID:** NCT05356585
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-30
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor already published research that was to be obtained from this study.
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05356585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05356585, "Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05356585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*